Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 1793-1804

  Qi, Xiaoli ^a   Zhang, Dianrui ^b   Xu, Xia ^a   Feng, Feifei ^b   Ren, Guijie ^a   Chu, Qianqian ^a   Zhang, Qiang ^c   Tian, Keli ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Bax; Bcl 2; Caspase 3; Cdc2; Cyclin B1

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; NANOPARTICLE; ORIDONIN; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CELL CYCLE PROTEIN; KAURANE DERIVATIVE; NANOMATERIAL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PANCREAS CANCER; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; WESTERN BLOTTING; DRUG EFFECT; METABOLISM; NANOMEDICINE; PANCREAS TUMOR; PATHOLOGY; SUSPENSION; TUMOR CELL LINE;

RABDOSIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DITERPENES, KAURANE; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUSPENSIONS;

EID: 84866772465     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29483     Document Type: Article

References (28)

1. Abelson PH. Medicine from plants. Science. 1990;247:513.
2. Fuji K, Node M, Sai M, Fujita E, Takeda S, Unemi N. Terpenoids. LIII. Antitumor activity of trichorabdals and related compounds. Chem Pharm Bull (Tokyo). 1989;37:1472-1476.
3. Han QB, Li ML, Li SH, Mou SH, Lin ZW, Sun HD. Ent-kaurane diterpenoids from Isodon rubescens var. lushanensis. Chem Pharm Bull (Tokyo). 2003;51:790-793.
4. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H, Koeffler HP. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol. 2003;23:1187-1193.
5. Li CY, Wang EQ, Cheng Y, Bao JK. Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol. 2011;43:701-704.
6. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005;26:579-588.
7. Jin HY, Tan XZ, Liu XF, Ding YJ. Downregulation of AP-1 gene expression is an initial event in the oridonin-mediated inhibition of colorectal cancer: studies in vitro and in vivo. J Gastroenterol Hepatol. 2011;26:706-715.
8. Müller MW, Friess H, Köninger J, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195:221-228.
9. Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;l28:1626-1641.
10. Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785-796.
11. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56:827-840.
12. Kesisoglou F, Panmai S, Wu YH. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-644.
13. Gao L, Zhang D, Chen M, Zheng T, Wang S. Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement. Drug Dev Ind Pharm. 2007;33: 1332-1339.
14. Lou HY, Zhang XM, Gao L, et al. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 2009;379:181-186.
15. Gao L, Zhang DR, Chen MH, et al. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspension. Int J Pharm. 2008;355:321-327.
16. Storm G, Belliot SO, Daemen T, Lasic DD. Surface medication of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17:31-48.
17. Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644:229-249.
18. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 1997;385: 637-640.
19. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995;376:37-43.
20. Denault JB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem Rev. 2002;102:4489-4500.
21. Philchenkov AA. Caspases as regulators of apoptosis and other cell functions. Biochemistry (Mosc). 2003;68:365-376.
22. Zou H, Li Y, Liu X, Wang X. An APAF-12Cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999;274:11549-11556.
23. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol. 1999;144:281-292.
24. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91-97.
25. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm. 1995;125:309-313.
26. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 2007;8:149-160.
27. 2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 2008;270:40-55.
28. 2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 2009;490:70-75.